Can Biotech's Trump Bump Last?

Source: The Life Sciences Report  (12/02/2016)
Can Biotech's Trump Bump Last?
In the weeks since Donald Trump's presidential election victory, the stock markets have ridden a wave into positive—and in the case of the Dow, record-breaking—territory. The so-called Trump Bump also sent biotech indices, flaccid for much of the year, up as much as 15%. With the election now nearly a month old, and hot-button issues such as drug pricing still in the press, industry watchers have begun to weigh in on what might happen in the biotech and pharma markets when Trump takes office. read more >

Agreement Launches RXi Pharmaceuticals into Dynamic Immuno-Oncology Arena

Source: The Life Sciences Report  (11/14/2016)
Agreement Launches RXi Pharmaceuticals into Dynamic Immuno-Oncology Arena
By securing an exclusive option to acquire MirImmune Inc., RXi Pharmaceuticals has expanded its reach into the "high-value" field of immuno-oncology, a move that has energized the company and prompted a pair of analysts to express optimism about RXi's future. read more >

Why the Election Is Not as Relevant to Drug Stocks as You Might Believe

Contributed Opinion
Source: Dr. Len Yaffe for The Life Sciences Report  (11/02/2016)
Why the Election Is Not as Relevant to Drug Stocks as You Might Believe
Due to drug pricing controversies, there has been much concern about how the outcome of the upcoming election will affect pharmaceutical stocks. Dr. Len Yaffe of Stoc*Doc Partners sheds light on the issues in this analysis of drug price negotiation policy, and focuses in on one California ballot proposition that aims to rein in costs. read more >

Exploring Solutions to Healthcare's Spending Crisis

Contributed Opinion
Source: Dr. Len Yaffe for The Life Sciences Report  (10/19/2016)
Exploring Solutions to Healthcare's Spending Crisis
Rising healthcare costs continue to preoccupy providers, patients, politicians and investors. Some cost increases stem from inefficiencies in the medical system, some from social and demographic trends, and others are a function of profit motives on the part of insurers and a few drug companies. In this article for The Life Sciences Report, Dr. Len Yaffe of Stoc*Doc Partners reviews the issues and proposes some cures. read more >

Analysts Keep Focus on DURECT's DUR-928

Source: The Life Sciences Report  (10/06/2016)
Analysts Keep Focus on DURECT's DUR-928
The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT to Pain Therapeutics, has not changed the view of several analysts who follow DURECT. They are focused on DUR-928 for NASH and impaired kidney function, indications that are of great interest to Big Pharma. read more >

Viveve's Treatment for Improving Women's Sexual Function May Leapfrog the Competition

Source: The Life Sciences Report  (10/05/2016)
Viveve's Treatment for Improving Women's Sexual Function May Leapfrog the Competition
Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function. read more >

Stock-Moving Catalysts Anticipated for Regeneus in Q4/16

Source: The Life Sciences Report  (09/28/2016)
Stock-Moving Catalysts Anticipated for Regeneus in Q4/16
Australian regenerative medicine company Regeneus Ltd. has a handful of stock-moving Q4/16 catalysts on the calendar, among them a potential licensing agreement for its mesenchymal stem cell technology in Japan. read more >
Expert Investing Ideas
NASDAQ Biotech ARCA Pharmaceutical

Imagin, a Better Way to Detect Bladder Cancer

Contributed Opinion
Source: Bob Moriarty for The Life Sciences Report  (09/20/2016)
Imagin, a Better Way to Detect Bladder Cancer
Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes. read more >

Regeneus Secures Government Funding for R&D

Source: The Life Sciences Report  (09/14/2016)
Regeneus Secures Government Funding for R&D
The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding. read more >

Three Shots on Goal in Q4/16 for DURECT Corp.

Source: The Life Sciences Report  (09/08/2016)
Three Shots on Goal in Q4/16 for DURECT Corp.
With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw & Co. Analyst Jim Molloy sees blue sky ahead for DURECT Corp. read more >

Soligenix's Diversified Pipeline Advances on All Fronts

Source: The Life Sciences Report  (08/31/2016)
Soligenix's Diversified Pipeline Advances on All Fronts
The late-stage biopharmaceutical company Soligenix has had a string of good news. Revenue is up, the FDA awarded orphan status to a key drug, and BARDA and NIAID have granted the firm additional funding, plus the company is developing vaccines against Ebola and ricin, and has several other ongoing trials. Analyst Grant Zeng of Zacks Investment Research assesses the landscape. read more >
Biotech Watchlist 2016